Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

20121,100 citationsJournal Articlebronze Open Access

Authors

Shaji Kumar · Mayo Clinic

Angela Dispenzieri

Abstract

Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Neuroendocrine Tumor Research Advances Coagulation, Bradykinin, Polyphosphates, and Angioedema

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 9, pp. 989-995

DOI: 10.1200/jco.2011.38.5724

Field-Weighted Citation Impact: 16.11

Command Palette

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

Authors

Abstract

Topics & Keywords

Publication Details